Provectus Biopharma (NYSE:PVCT) was the target of a large decline in short interest in September. As of September 15th, there was short interest totalling 2,487,008 shares, a decline of 13.0% from the August 31st total of 2,858,468 shares. Based on an average daily volume of 3,843,492 shares, the days-to-cover ratio is presently 0.6 days. Approximately 1.2% of the company’s stock are sold short.

Shares of Provectus Biopharma (NYSE:PVCT) opened at 0.0992 on Friday. The stock has a 50 day moving average of $0.15 and a 200 day moving average of $0.31. The company’s market cap is $21.11 million. Provectus Biopharma has a 12-month low of $0.09 and a 12-month high of $0.60.

Provectus Biopharma Company Profile

Provectus Biopharmaceuticals, Inc is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer.

5 Day Chart for NYSE:PVCT

Receive News & Stock Ratings for Provectus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharma and related stocks with our FREE daily email newsletter.